KEY FEATURES
| Full Name | Early Growth Response Protein 1 |
|---|---|
| Synonym | Zif268; AT225; G0S30; KROX24; NGFI-A; TIS8; ZIF-268; ZNF225; NGFIA; TIS8; ZENK; Nerve Growth Factor-Induced Protein A; Transcription Factor ETR103; Zinc Finger Protein 225 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.15-10ng/mL |
| Sensitivity | 0.06ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human EGR1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human EGR1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human EGR1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human EGR1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human EGR1. You can calculate the concentration of Human EGR1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human EGR1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.5 | 1.53 | 3.54 | 0.46 | 1.55 | 3.87 |
| Standard deviation | 0.03 | 0.09 | 0.12 | 0.02 | 0.07 | 0.12 |
| CV(%) | 5.76 | 5.78 | 3.31 | 5.1 | 4.54 | 3.2 |
RECOVERY
The recovery of Human EGR1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 90-103 | 98 |
| EDTA plasma (n=8) | 90-102 | 96 |
| Cell culture media (n=8) | 93-108 | 99 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human EGR1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with EGR1 ELISA Kits
| FOS ELISA Kit | publications with EGR1 and FOS |
| JUN ELISA Kit | publications with EGR1 and JUN |
| NAB2 ELISA Kit | publications with EGR1 and NAB2 |
| ELK1 ELISA Kit | publications with EGR1 and ELK1 |
| ATF3 ELISA Kit | publications with EGR1 and ATF3 |
| NAB1 ELISA Kit | publications with EGR1 and NAB1 |
| TP53 ELISA Kit | publications with EGR1 and TP53 |
| NFATC2 ELISA Kit | publications with EGR1 and NFATC2 |
| SNAI1 ELISA Kit | publications with EGR1 and SNAI1 |
| NFATC1 ELISA Kit | publications with EGR1 and NFATC1 |
Pathways associated with EGR1 ELISA Kit
| BDNF Signaling Pathway | BDNF Signaling Pathway |
| Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway | Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway |
| Cytokine Signaling In Immune System Pathway | Cytokine Signaling In Immune System Pathway |
| Downstream Signaling In Naive CD8+ T Cells Pathway | Downstream Signaling In Naive CD8+ T Cells Pathway |
| ErbB1 Downstream Signaling Pathway | ErbB1 Downstream Signaling Pathway |
| Glucocorticoid Receptor Regulatory Network Pathway | Glucocorticoid Receptor Regulatory Network Pathway |
| HTLV-I Infection Pathway | HTLV-I Infection Pathway |
| Immune System Pathway | Immune System Pathway |
| Insulin Signaling Pathway | Insulin Signaling Pathway |
Diseases associated with EGR1 ELISA Kit
| Nervous System Diseases | publications with EGR1 and Nervous System Diseases |
| Inflammation | publications with EGR1 and Inflammation |
| Cardiovascular Diseases | publications with EGR1 and Cardiovascular Diseases |
| Disease Models, Animal | publications with EGR1 and Disease Models, Animal |
| Necrosis | publications with EGR1 and Necrosis |
| Brain Diseases | publications with EGR1 and Brain Diseases |
| Ischemia | publications with EGR1 and Ischemia |
| Prostatic Neoplasms | publications with EGR1 and Prostatic Neoplasms |
| Breast Neoplasms | publications with EGR1 and Breast Neoplasms |
| Liver Diseases | publications with EGR1 and Liver Diseases |
Organs/Tissues associated with EGR1 ELISA Kit
| Brain | publications with EGR1 and Brain |
| Blood | publications with EGR1 and Blood |
| Nerve | publications with EGR1 and Nerve |
| Vascular | publications with EGR1 and Vascular |
| Muscle | publications with EGR1 and Muscle |
| Lung | publications with EGR1 and Lung |
| Liver | publications with EGR1 and Liver |
| Kidney | publications with EGR1 and Kidney |
| Bone | publications with EGR1 and Bone |
| Prostate | publications with EGR1 and Prostate |